<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02472366</url>
  </required_header>
  <id_info>
    <org_study_id>M-01-13-002</org_study_id>
    <nct_id>NCT02472366</nct_id>
  </id_info>
  <brief_title>A Non-Randomized, Open-Label, Single Center Phase 4 Study of the Effect and Safety of ILUVIEN® in Chronic Diabetic Macular Edema Patients Considered Insufficiently Responsive to Available Therapies (Laser, Anti-VEGF) With or Without Intravitreal Corticosteroid Therapy</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alimera Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alimera Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 4 trial evaluating the effect and safety of ILUVIEN in chronic DME patients
      insufficiently responsive to available therapies.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Best Corrected Visual Acuity From Baseline</measure>
    <time_frame>Change from Baseline to 12 months post ILUVIEN administration</time_frame>
    <description>Best Corrected Visual Acuity is measured using an ETDRS eye chart and is reported as the number of letters read correctly in the study and/or fellow eye.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Intraocular Pressure (IOP)</measure>
    <time_frame>Change from Baseline to 12 months post ILUVIEN administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Central Subfield Thickness</measure>
    <time_frame>Change from Baseline to 12 months post ILUVIEN administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Macular Volume</measure>
    <time_frame>Change from Baseline to 12 months post ILUVIEN administration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Chronic Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>laser</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>laser with or without prior history of intraocular corticosteroid therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>laser and anti-VEGF</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>laser and anti-VEGF therapy with or without prior history of intraocular corticosteroid therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ILUVIEN</intervention_name>
    <arm_group_label>laser</arm_group_label>
    <arm_group_label>laser and anti-VEGF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients ≥18 years of age, of either sex that have signed informed consent / been well
             informed by the treating physician.

          2. DME based on investigator's clinical evaluation and demonstrated using fundoscopic
             photography and spectral domain OCT.

          3. Mean central foveal thickness (central subfield thickness) ≥350 microns in the study
             eye as measured using spectral domain OCT.

          4. Vision impairment (20/60 to 20/400 using Snellen visual acuity equivalent) related to
             DME.

          5. Previous treatment in the study eye with laser photocoagulation for DME, including
             focal/grid and pan-retinal, at least 3 months prior to the screening visit and ≥3
             monthly anti-VEGF treatments (group 1).

          6. Previous treatment in the study eye with laser photocoagulation for DME at least 3
             months prior to the screening visit (group 2) and treatment with an intraocular
             anti-VEGF therapy not possible.

          7. Patients considered as insufficiently responsive to prior therapy for DME, as defined
             by the study physician.

        Exclusion Criteria:

          1. IOP &gt;21 mmHg at screening in the study eye.

          2. Historical rise in IOP &gt;25 mmHg following treatment with an intravitreal
             corticosteroid in the study eye.

          3. Use of ≥2 IOP-lowering medications to control IOP at screening in the study eye.

          4. Patients that have vitreomacular traction in DME and opaque media in the study eye.

          5. Patients with severe proliferative diabetic retinopathy requiring pan retinal
             photocoagulation in the study eye.

          6. Pregnant or breastfeeding.

          7. Patients diagnosed with active angiographic central vein ischaemia prior to screening
             in the study eye.

          8. Patients that have received pan retinal photocoagulation or undergone cataract surgery
             in the 3 months prior to the study start date in the study eye.

          9. Patients with contraindications according to the current SPC:

               1. The presence of pre-existing glaucoma.

               2. Active or suspected ocular or periocular infection.

               3. The patient is hypersensitive to the active agent or to one of the excipients.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2015</study_first_submitted>
  <study_first_submitted_qc>June 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2015</study_first_posted>
  <results_first_submitted>June 23, 2015</results_first_submitted>
  <results_first_submitted_qc>August 14, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 16, 2015</results_first_posted>
  <last_update_submitted>August 14, 2015</last_update_submitted>
  <last_update_submitted_qc>August 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Fluocinolone Acetonide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Laser</title>
          <description>laser with or without prior history of intraocular corticosteroid therapy
ILUVIEN</description>
        </group>
        <group group_id="P2">
          <title>Laser and Anti-VEGF</title>
          <description>laser and anti-VEGF therapy with or without prior history of intraocular corticosteroid therapy
ILUVIEN</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6">6 subjects receiving ILUVIEN, 7 eyes receiving ILUVIEN</participants>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Laser</title>
          <description>laser with or without prior history of intraocular corticosteroid therapy
ILUVIEN</description>
        </group>
        <group group_id="B2">
          <title>Laser and Anti-VEGF</title>
          <description>laser and anti-VEGF therapy with or without prior history of intraocular corticosteroid therapy
ILUVIEN</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.65" spread="9.014"/>
                    <measurement group_id="B2" value="60.87" spread="11.006"/>
                    <measurement group_id="B3" value="63.04" spread="10.398"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changes in Best Corrected Visual Acuity From Baseline</title>
        <description>Best Corrected Visual Acuity is measured using an ETDRS eye chart and is reported as the number of letters read correctly in the study and/or fellow eye.</description>
        <time_frame>Change from Baseline to 12 months post ILUVIEN administration</time_frame>
        <population>For the &quot;Laser&quot; arm group, 6 patients were enrolled and 7 eyes were treated with ILUVIEN</population>
        <group_list>
          <group group_id="O1">
            <title>Laser</title>
            <description>laser with or without prior history of intraocular corticosteroid therapy
ILUVIEN</description>
          </group>
          <group group_id="O2">
            <title>Laser and Anti-VEGF</title>
            <description>laser and anti-VEGF therapy with or without prior history of intraocular corticosteroid therapy
ILUVIEN</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Best Corrected Visual Acuity From Baseline</title>
          <description>Best Corrected Visual Acuity is measured using an ETDRS eye chart and is reported as the number of letters read correctly in the study and/or fellow eye.</description>
          <population>For the &quot;Laser&quot; arm group, 6 patients were enrolled and 7 eyes were treated with ILUVIEN</population>
          <units>Best Corrected VA Letter Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="7.40"/>
                    <measurement group_id="O2" value="0.9" spread="15.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Intraocular Pressure (IOP)</title>
        <time_frame>Change from Baseline to 12 months post ILUVIEN administration</time_frame>
        <population>for &quot;laser&quot; arm group, 6 patients enrolled with 7 eyes receiving ILUVIEN</population>
        <group_list>
          <group group_id="O1">
            <title>Laser</title>
            <description>laser with or without prior history of intraocular corticosteroid therapy
ILUVIEN</description>
          </group>
          <group group_id="O2">
            <title>Laser and Anti-VEGF</title>
            <description>laser and anti-VEGF therapy with or without prior history of intraocular corticosteroid therapy
ILUVIEN</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Intraocular Pressure (IOP)</title>
          <population>for &quot;laser&quot; arm group, 6 patients enrolled with 7 eyes receiving ILUVIEN</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="1.86"/>
                    <measurement group_id="O2" value="2.9" spread="6.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Central Subfield Thickness</title>
        <time_frame>Change from Baseline to 12 months post ILUVIEN administration</time_frame>
        <population>For &quot;Laser&quot; arm group, there were 6 patients enrolled but 7 eyes treated</population>
        <group_list>
          <group group_id="O1">
            <title>Laser</title>
            <description>laser with or without prior history of intraocular corticosteroid therapy
ILUVIEN</description>
          </group>
          <group group_id="O2">
            <title>Laser and Anti-VEGF</title>
            <description>laser and anti-VEGF therapy with or without prior history of intraocular corticosteroid therapy
ILUVIEN</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Central Subfield Thickness</title>
          <population>For &quot;Laser&quot; arm group, there were 6 patients enrolled but 7 eyes treated</population>
          <units>microns</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-362.2" spread="130.59"/>
                    <measurement group_id="O2" value="-251.3" spread="268.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Macular Volume</title>
        <time_frame>Change from Baseline to 12 months post ILUVIEN administration</time_frame>
        <population>For &quot;laser&quot; arm group, 6 patients were enrolled with 7 eyes receiving ILUVIEN</population>
        <group_list>
          <group group_id="O1">
            <title>Laser</title>
            <description>laser with or without prior history of intraocular corticosteroid therapy
ILUVIEN</description>
          </group>
          <group group_id="O2">
            <title>Laser and Anti-VEGF</title>
            <description>laser and anti-VEGF therapy with or without prior history of intraocular corticosteroid therapy
ILUVIEN</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Macular Volume</title>
          <population>For &quot;laser&quot; arm group, 6 patients were enrolled with 7 eyes receiving ILUVIEN</population>
          <units>mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.610" spread="1.1979"/>
                    <measurement group_id="O2" value="-1.137" spread="3.4345"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Change in Best Corrected Visual Acuity From Baseline</title>
        <description>A subgroup analysis was performed in which only pseudophakic subjects were included. Best Corrected Visual Acuity is measured using an ETDRS eye chart and is reported as the number of letters read correctly in the study and/or fellow eye.</description>
        <time_frame>Change from Baseline to 12 months post ILUVIEN administration</time_frame>
        <population>For the &quot;Laser&quot; arm group, 6 patients were enrolled and 7 eyes were treated with ILUVIEN</population>
        <group_list>
          <group group_id="O1">
            <title>Laser</title>
            <description>laser with or without prior history of intraocular corticosteroid therapy
ILUVIEN</description>
          </group>
          <group group_id="O2">
            <title>Laser and Anti-VEGF</title>
            <description>laser and anti-VEGF therapy with or without prior history of intraocular corticosteroid therapy
ILUVIEN</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Best Corrected Visual Acuity From Baseline</title>
          <description>A subgroup analysis was performed in which only pseudophakic subjects were included. Best Corrected Visual Acuity is measured using an ETDRS eye chart and is reported as the number of letters read correctly in the study and/or fellow eye.</description>
          <population>For the &quot;Laser&quot; arm group, 6 patients were enrolled and 7 eyes were treated with ILUVIEN</population>
          <units>Best Corrected VA Letter Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" spread="8.70"/>
                    <measurement group_id="O2" value="9.4" spread="11.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The safety and tolerability of ILUVIEN was monitored over 12 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Laser</title>
          <description>laser with or without prior history of intraocular corticosteroid therapy
ILUVIEN</description>
        </group>
        <group group_id="E2">
          <title>Laser and Anti-VEGF</title>
          <description>laser and anti-VEGF therapy with or without prior history of intraocular corticosteroid therapy
ILUVIEN</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cataract Surgery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vitrectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Intra-ocular pressure (30 mmHg)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Intra-ocular pressure (25mmHG)</sub_title>
                <description>1 event occurred in the fellow eye</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Intra-ocular pressure (28mmHg)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dislocated Shoulder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Professor Pascale Massin</name_or_title>
      <organization>Hopital Lariboisiere</organization>
      <phone>0149 95 24 74</phone>
      <email>pascale.massin@lrb.aphp.FR</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

